Loading
PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes. In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signalling and promotes development to the mature B-cell stage.
CIViC holds 5 clinical evidence items and 1 assertion across 2 variants. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.98, animal model 0.27, genetic association 0.45, somatic mutation 0.83). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Prostate Adenocarcinoma.
In plain words · PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes.
No product in this corpus aims at PAX5 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PAX5: RNA tissue enriched (lymphoid tissue 37 nTPM); blood lineage lineage enriched (B-cells 39 nTPM); high antibody staining in 1 normal tissue; highest cancer staining lymphoma (8 of 11 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Breast cancer (all types), Skin cancer (all types), Prostate cancer, Lung cancer (all types)); Open Targets associates it with 2 specific cancer types at or above 0.5 (leukemia, acute lymphoblastic, susceptibility to, 3, acute lymphoblastic leukemia). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q02548; CIViC gene PAX5; IntOGen PAX5; Human Protein Atlas PAX5 tissue; Open Targets ENSG00000196092 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Adams et al, Genes Dev, 1992, "Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis". Source.
Sources: HGNC HGNC:8619 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02548 (protein name, function text, keywords and locations (REST API)); CIViC gene PAX5 (5 evidence items, 1 assertions, 2 variants; diseases: B-lymphoblastic Leukaemia With PAX5 P.P80R, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000196092 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: melanoma 0.56, acute lymphoblastic leukaemia 0.67, non-Hodgkin lymphoma 0.71, skin cancer 0.57, breast cancer 0.61, lung cancer 0.54 (GraphQL API, CC0)); IntOGen PAX5 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes. In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signalling and promotes development to the mature B-cell stage. Repression of the cohesin-release factor WAPL causes global changes of the chromosomal architecture in pro-B cells to facilitate the generation of a diverse antibody repertoire. Also participates in the inhibition of lytic EBV reactivation by modulating viral BZLF1 activity. Location: Nucleus (UniProt). Locus 9p13.2 (HGNC).
RNA: tissue enriched (lymphoid tissue 37 nTPM), detected in some normal tissues. Blood: lineage enriched (B-cells 39 nTPM).
Medium: Appendix, Bone marrow, Lymph node, Spleen.
RNA cancer enhanced: Stomach Adenocarcinoma 4 pTPM.
Medium only: cervical cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PAX5" OR ABSTRACT:"PAX5" OR TITLE:"paired box 5" OR ABSTRACT:"paired box 5" OR TITLE:"Paired box protein Pax-5" OR ABSTRACT:"Paired box protein Pax-5" OR TITLE:"PAX-5" OR ABSTRACT:"PAX-5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PAX5, not a curated reading list.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).